<DOC>
	<DOCNO>NCT02051426</DOCNO>
	<brief_summary>The efficacy compound agonistic activity glycine site associate N-methyl-D-aspartate receptor ( NMDAR ) presently assess psychiatric disorder . In contrast NMDAR antagonist , neuropsychiatric effect NMDAR agonists healthy human organism know . The investigator study neuropsychiatric neurochemical effect NMDAR-glycine site obligatory co-agonist D-serine ( DSR ) healthy subject use randomize , control crossover challenge design include baseline assessment day two treatment administration day ( DSR placebo randomize order ) . Thirty-five subject age 23-29 year participate study receive 2.1g orally administer DSR dose . The main outcome measure change score mood-related Visual Analogue Scale ( VAS ) , Continuous Performance Test - Identical Pairs ( CPT-IP ) , Rey Auditory Verbal Learning Test ( RAVLT ) .</brief_summary>
	<brief_title>Behavioral Cognitive Effects N-methyl-D-aspartate Receptor ( NMDAR ) Co-agonist D-serine Healthy Humans</brief_title>
	<detailed_description>The study employ randomize , double-blind , placebo control crossover design accord , follow baseline assessment session , subject test two acute treatment condition two separate day . Following baseline assessment day , 16 subject randomize , use computer-generated random number sequence , receive test day 1 DSR 19 receive placebo . During test day 2 , two group subject cross receive alternative experimental treatment . The time interval baseline assessment day , test day 1 test day 2 two three week 1 month respectively , order avoid possibility carry-over effect .</detailed_description>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>healthy volunteer history psychiatric , medical , neurological illness substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>neuropsychiatric effect</keyword>
</DOC>